HK1117160A1 - Crystals of laquinimod sodium, and process for the manufacture thereof (laquinimod sodium) - Google Patents

Crystals of laquinimod sodium, and process for the manufacture thereof (laquinimod sodium)

Info

Publication number
HK1117160A1
HK1117160A1 HK08112048.9A HK08112048A HK1117160A1 HK 1117160 A1 HK1117160 A1 HK 1117160A1 HK 08112048 A HK08112048 A HK 08112048A HK 1117160 A1 HK1117160 A1 HK 1117160A1
Authority
HK
Hong Kong
Prior art keywords
laquinimod sodium
crystals
manufacture
laquinimod
sodium
Prior art date
Application number
HK08112048.9A
Other languages
English (en)
Chinese (zh)
Inventor
Anton Frenkel
Eduard Gurevich
Avital Laxer
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HK1117160A1 publication Critical patent/HK1117160A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
HK08112048.9A 2005-10-19 2008-11-03 Crystals of laquinimod sodium, and process for the manufacture thereof (laquinimod sodium) HK1117160A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72865705P 2005-10-19 2005-10-19
PCT/US2006/040925 WO2007047863A2 (en) 2005-10-19 2006-10-18 Crystals of laquinimod sodium, and process for the manufacture thereof

Publications (1)

Publication Number Publication Date
HK1117160A1 true HK1117160A1 (en) 2009-01-09

Family

ID=37963287

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08112048.9A HK1117160A1 (en) 2005-10-19 2008-11-03 Crystals of laquinimod sodium, and process for the manufacture thereof (laquinimod sodium)

Country Status (24)

Country Link
US (4) US7884208B2 (xx)
EP (2) EP2687512A1 (xx)
JP (3) JP5832716B2 (xx)
KR (1) KR101440982B1 (xx)
CN (3) CN103333107A (xx)
AR (1) AR056708A1 (xx)
AU (1) AU2006304672B2 (xx)
BR (1) BRPI0617477A2 (xx)
CA (1) CA2625287C (xx)
DK (1) DK1937642T3 (xx)
ES (1) ES2523762T3 (xx)
HK (1) HK1117160A1 (xx)
HR (1) HRP20141160T1 (xx)
IL (1) IL190137A (xx)
NZ (2) NZ592897A (xx)
PL (1) PL1937642T3 (xx)
PT (1) PT1937642E (xx)
RS (1) RS53666B1 (xx)
RU (1) RU2415841C2 (xx)
SG (1) SG10201508623RA (xx)
SI (1) SI1937642T1 (xx)
UA (1) UA92761C2 (xx)
WO (1) WO2007047863A2 (xx)
ZA (1) ZA200803527B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SI1937642T1 (sl) * 2005-10-19 2015-01-30 Teva Pharmaceutical Industries Ltd. Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
KR20160013273A (ko) * 2006-06-12 2016-02-03 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
WO2010001257A2 (en) * 2008-07-01 2010-01-07 Actavis Group Ptc Ehf Novel solid state forms of laquinimod and its sodium salt
CA2736091A1 (en) * 2008-09-03 2010-03-11 Teva Pharmaceutical Industries Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
WO2010070449A2 (en) 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
US20100322900A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
CA2769623A1 (en) * 2009-07-30 2011-02-03 Teva Pharmaceutical Industries Ltd. Treatment of crohn's disease with laquinimod
ES2586843T3 (es) 2009-08-10 2016-10-19 Teva Pharmaceutical Industries Ltd. Tratamiento de trastornos relacionados con BDNF usando laquinimod
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
MX337614B (es) * 2010-03-03 2016-03-10 Teva Pharma Tratamiento de lupus nefritis usando laquinimod.
SI2542079T1 (sl) * 2010-03-03 2014-08-29 Teva Pharmaceutical Industries Ltd. Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata
NZ602512A (en) * 2010-03-03 2014-07-25 Teva Pharma Treatment of lupus arthritis using laquinimod
EP3213636A1 (en) * 2010-07-09 2017-09-06 Teva Pharmaceutical Industries, Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
KR20130041193A (ko) 2010-07-09 2013-04-24 테바 파마슈티컬 인더스트리즈 리미티드 5-클로로-4-하이드록시-1-메틸-2-옥소-n-페닐-1,2-다이하이드로퀴놀린-3-카복스아마이드, 염 및 그의 용도
MX2013005954A (es) * 2010-11-28 2013-07-29 Mapi Pharma Ltd Compuestos intermedios y procesos para la preparacion de derivados de quinolina tal como laquinimod sodico.
CN106344576A (zh) * 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
JP2015505564A (ja) 2012-02-03 2015-02-23 テバ ファーマシューティカル インダストリーズ リミティド 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
MX2014009889A (es) * 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CN103626701A (zh) * 2012-08-28 2014-03-12 天津药物研究院 一种制备喹啉衍生物的方法
CN103626702A (zh) * 2012-08-30 2014-03-12 天津药物研究院 一种制备喹啉酮衍生物的方法
WO2014033954A1 (ja) 2012-09-03 2014-03-06 トヨタ自動車株式会社 衝突判定装置及び衝突判定方法
JP2015535287A (ja) 2012-11-07 2015-12-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドのアミン塩
SG11201506409RA (en) 2013-03-14 2015-09-29 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
MX2015010967A (es) 2013-03-14 2015-10-26 Teva Pharma Formulaciones transdermicas de laquinimod.
JP2016537365A (ja) 2013-11-15 2016-12-01 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用
MX2016013944A (es) 2014-04-29 2017-01-09 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis multiple recidivante-remitente (rrms) con un alto estado de discapacidad.

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613574A (en) * 1898-11-01 Feed-regulator
US3024257A (en) * 1961-04-10 1962-03-06 Frosst & Co Charles E Stable preparations of alkali metal salts of estrone sulfate
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
CH687615A5 (de) 1994-09-07 1997-01-15 R W Johnson Pharmaceutical Res Tropen-Verpackung.
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
US6256814B1 (en) 1997-09-19 2001-07-10 Cosco Management, Inc. Playyard
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
TR200103527T2 (tr) 1999-06-07 2002-04-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Bir asit-labil aktif bileşik içeren yeni hazırlama ve uygulama şekli
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
RS51019B (sr) * 1999-10-25 2010-10-31 Active Biotech Ab. Lekovi za lečenje malignih tumora
JP2002031610A (ja) 2000-07-14 2002-01-31 Ajinomoto Co Inc 生体分子複合体の界面残基を同定する方法
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6802422B2 (en) * 2000-12-12 2004-10-12 Multi-Comp, Inc. Sealed blister assembly
US6706733B2 (en) * 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US20030119826A1 (en) * 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
EP1386926A1 (en) 2002-07-29 2004-02-04 Bioxtal Methods for producing labelled recombinant polypeptides and uses thereof
ITMI20021726A1 (it) 2002-08-01 2004-02-02 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
EP1694308A1 (en) 2003-10-30 2006-08-30 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SI1937642T1 (sl) * 2005-10-19 2015-01-30 Teva Pharmaceutical Industries Ltd. Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
KR20160013273A (ko) 2006-06-12 2016-02-03 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
WO2010001257A2 (en) 2008-07-01 2010-01-07 Actavis Group Ptc Ehf Novel solid state forms of laquinimod and its sodium salt
CA2736091A1 (en) 2008-09-03 2010-03-11 Teva Pharmaceutical Industries Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
US20100322900A1 (en) 2009-06-19 2010-12-23 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
CA2769623A1 (en) 2009-07-30 2011-02-03 Teva Pharmaceutical Industries Ltd. Treatment of crohn's disease with laquinimod
ES2586843T3 (es) 2009-08-10 2016-10-19 Teva Pharmaceutical Industries Ltd. Tratamiento de trastornos relacionados con BDNF usando laquinimod
MX337614B (es) 2010-03-03 2016-03-10 Teva Pharma Tratamiento de lupus nefritis usando laquinimod.
NZ602512A (en) 2010-03-03 2014-07-25 Teva Pharma Treatment of lupus arthritis using laquinimod
SI2542079T1 (sl) 2010-03-03 2014-08-29 Teva Pharmaceutical Industries Ltd. Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata
EP3213636A1 (en) 2010-07-09 2017-09-06 Teva Pharmaceutical Industries, Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
KR20130041193A (ko) 2010-07-09 2013-04-24 테바 파마슈티컬 인더스트리즈 리미티드 5-클로로-4-하이드록시-1-메틸-2-옥소-n-페닐-1,2-다이하이드로퀴놀린-3-카복스아마이드, 염 및 그의 용도
US20120055072A1 (en) * 2010-09-08 2012-03-08 Rankin Sammy D Directional guide for fishing lures
PE20140872A1 (es) 2010-12-07 2014-08-09 Teva Pharma Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple

Also Published As

Publication number Publication date
US20140171647A1 (en) 2014-06-19
BRPI0617477A2 (pt) 2011-07-26
US7884208B2 (en) 2011-02-08
ZA200803527B (en) 2009-09-30
JP2013100299A (ja) 2013-05-23
US20110118308A1 (en) 2011-05-19
ES2523762T3 (es) 2014-12-01
PT1937642E (pt) 2014-11-25
US8673322B2 (en) 2014-03-18
IL190137A (en) 2015-06-30
RU2008119456A (ru) 2009-11-27
US8647646B2 (en) 2014-02-11
SG10201508623RA (en) 2015-11-27
CN101291911A (zh) 2008-10-22
JP2009512708A (ja) 2009-03-26
CA2625287A1 (en) 2007-04-26
US20070088050A1 (en) 2007-04-19
IL190137A0 (en) 2008-08-07
PL1937642T3 (pl) 2015-02-27
SI1937642T1 (sl) 2015-01-30
EP1937642A2 (en) 2008-07-02
AU2006304672A1 (en) 2007-04-26
CN101291911B (zh) 2014-08-13
NZ567088A (en) 2012-06-29
CN103333107A (zh) 2013-10-02
DK1937642T3 (en) 2014-12-15
EP1937642A4 (en) 2009-03-18
KR101440982B1 (ko) 2014-09-17
EP1937642B1 (en) 2014-09-10
CA2625287C (en) 2016-07-26
JP2016020353A (ja) 2016-02-04
RS53666B1 (en) 2015-04-30
UA92761C2 (ru) 2010-12-10
AU2006304672B2 (en) 2013-01-10
RU2415841C2 (ru) 2011-04-10
JP5832716B2 (ja) 2015-12-16
WO2007047863A2 (en) 2007-04-26
AR056708A1 (es) 2007-10-17
CN107176923A (zh) 2017-09-19
EP2687512A1 (en) 2014-01-22
HRP20141160T1 (hr) 2015-01-16
NZ592897A (en) 2012-12-21
US20110112141A1 (en) 2011-05-12
WO2007047863A3 (en) 2007-06-28
KR20080064978A (ko) 2008-07-10

Similar Documents

Publication Publication Date Title
HK1117160A1 (en) Crystals of laquinimod sodium, and process for the manufacture thereof (laquinimod sodium)
IL192241A (en) A process for making 4 - (benzimidazolylmethylamino) - benzamides and their salts
EP1925617A4 (en) Heterocyclic compound, method of preparation and use
SI1797037T1 (sl) Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida
PL1844036T3 (pl) Sposób otrzymywania arypiprazolu
EP1916241A4 (en) CRYSTAL OF A PHENYLALANINE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND ITS USE
ZA200804264B (en) Process for the preparation of ferri-succinylcasein
ZA200710914B (en) Process for the preparation of sulfonamide derivatives
IL187025A0 (en) Hard caramel containing isolmaltulose and process for the manufacture thereof
EP1867623A4 (en) Terephthalic derivatives, tetrahalothiophenyl derivatives and processes for their preparation
EP1984327A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF CILASTATIN AND ITS SODIUM SALT
ZA200601910B (en) Process for the preparation of organosilances
PL1763508T3 (pl) Sposób wytwarzania mocznika
GB2436262B (en) Process for the preparation of pantoprazole sodium
IL213474A0 (en) Processes for the preparation of cyclopropyl-amide derivatives
EP1968942A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF SODIUM MONTELUKAST
IL190963A0 (en) Novel processes for the preparation of piperazinly and diazapanyl benzamide derivatives
EP1831171A4 (en) PROCESS FOR THE PREPARATION OF NEW MONTELUKAST SODIUM AMORPHOUS
IL186457A0 (en) Process for the preparation of 9,10-dehydro-12,13-desoxyepothilone derivatives
HUP0401379A3 (en) Process for the preparation of risperidon
HUP0500570A3 (en) Process for the preparation of (s)-(-)-amlodipine
ZA200706203B (en) Processes and compounds for the preparation of substituted naphthylindole derivatives
EP1915380A4 (en) PROCESS FOR THE SYNTHESIS OF N, N'-DISUBSTITUTED OXABISPIDINES
SI1732916T1 (sl) Postopek za pripravo alkoksikarbonilmetoksi-ciklopentanov
PL373687A1 (en) Method for manufacture of 4',5,7-trihydroxyflavone

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE NAME OF APPLICANT FROM TEVA PHARMACEUTICAL INDUSTRIES LIMITED TO TEVA PHARMACEUTICAL INDUSTRIES LTD

Effective date: 20160121

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191023